Part the Cloud Translational Research for Alzheimer’s Disease Program: Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) Funding Program
Funds research that advances AI-discovered, disease-modifying therapeutic candidates for Alzheimer’s disease from lead optimization to IND-enabling studies, bridging computational discovery and experimental validation.
Funder: Alzheimer's Association
Due Dates (Anticipated): March 2027 (Letter of Intent) | April 2027 (Full application)
Funding Amounts: Up to $1,000,000 total (direct + indirect) over up to three years; indirect costs capped at 10% for non-profits only.
Summary: Supports advancement of AI-discovered therapeutic leads for Alzheimer’s disease from lead optimization through IND-enabling studies.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
This program, offered by the Alzheimer's Association under the "Part the Cloud" initiative, aims to bridge the gap between artificial intelligence (AI)-driven therapeutic discovery and experimental validation for Alzheimer’s disease and related dementias. It specifically funds projects that advance AI- or machine learning-derived therapeutic candidates through critical stages—lead optimization and IND-enabling studies—toward clinical development. Both small molecules and biologics are eligible, provided the approach is disease-modifying and not purely symptomatic.
